(Q45004319)

8 December 2017

title

Differential qualitative responses to rivastigmine in APOE epsilon 4 carriers and noncarriers (English)

1 reference

8 December 2017

M Farlow

1

1 reference

8 December 2017

R Lane

series ordinal

2

1 reference

8 December 2017

S Kudaravalli

series ordinal

3

1 reference

8 December 2017

Y He

series ordinal

4

1 reference

8 December 2017

publication date

1 January 2004

1 reference

The Pharmacogenomics Journal

8 December 2017

published in

1 reference

8 December 2017

volume

4

1 reference

8 December 2017

issue

5

1 reference

8 December 2017

page(s)

332-335

1 reference

New frontiers in Alzheimer's disease genetics

8 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500267

Apolipoprotein E: a major piece in the Alzheimer's disease puzzle.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500267

Genetic susceptibility factors for Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500267

Genome-wide linkage disequilibrium mapping of late-onset Alzheimer's disease in Finland.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500267

Apolipoprotein E genetic variation and Alzheimer's disease. a meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500267

Using meta-analysis to explain the diversity of results in genetic studies of late-onset Alzheimer's disease and to identify high-risk subgroups.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500267

Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500267

APOE genotype: no influence on galantamine treatment efficacy nor on rate of decline in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500267

Galantamine in AD: A 6-month randomized, placebo-controlled trial with a 6-month extension. The Galantamine USA-1 Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500267

Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: multicentre randomised controlled trial. Galantamine International-1 Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500267

Treatment outcome of tacrine therapy depends on apolipoprotein genotype and gender of the subjects with Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500267

Economic considerations in the treatment and management of Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500267

inferred from DOI database lookup

7 January 2021

based on heuristic

Alzheimer's disease: genes, proteins, and therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500267

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1038/SJ.TPJ.6500267

1 reference

Dimensions Publication ID

8 December 2017

1010957977

0 references

1 reference